AXON Nasdaq Aerospace & Defense Financials FY2016βFY2025
Axon sells technology to police, other public safety agencies and some private customers. It describes itself as a company that sells both hardware and software that work together. Its products include TASER stun devices, body cameras, in-car and fixed cameras, drones, and cloud software for storing and sharing video evidence, writing reports and running real-time operations. Many of its software tools use artificial intelligence.
Hi! I read Axon Enterpriseβs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+33.5%
Yes. Sales grew 33.5% last year.
Does it make a profit?
4.5%
A little. It keeps 4.5% of every sale as profit.
Does profit turn into cash?
2.7%
Partly. 2.7% of sales ends up as free cash.
Is debt under control?
4.9x
Heavy. Repaying its debt would take 4.9 years of operating profit.
How healthy are the accounts?
6 / 9
Mixed. It passes 6 of 9 health tests.
How is the share priced?
176.3x
One share costs 176.3 times its yearly profit per share. Typical for its sector: 26.0x.
Rules of thumb on reported numbers. A starting point, not a recommendation.
About these figures. Axon had no borrowings before it issued convertible notes in December 2022 (its credit line was undrawn), so debt counts as zero in earlier years. In 2024 Axon's convertible notes were due within a year and its amended 10-K moved them to a current line, which is counted as debt.
Is it selling more, and how much does it keep?
KIRA Β· Axon Enterprise had $2.8B of revenue in fiscal 2025, up 33.5% on the year before. Over five years, revenue changed +32.5% a year on average. Its operating margin was β2.2%, down 5.0Β pts: of every 100 in sales, about β2 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Axon Enterprise made $125M of net profit in fiscal 2025. From fiscal 2016 to 2025, diluted EPS grew 18.8% a year.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was $75.1M in fiscal 2025, 2.7% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
KIRA Β· Axon Enterprise returned $0.0M to shareholders in fiscal 2025, 0% of free cash flow. The diluted share count rose 4.9%.
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· In the last 12 months, insiders sold $130M of shares on the open market and bought none.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$130M
11 insiders
Of sales under plans
63%
$81.3M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 11, 2026 | Isaiah FieldsChief Legal Officer | Sold plan | 1,017 | $480.45 | $0.5M | Form 4 |
| Sep 8, 2026 | Patrick W SmithChief Executive Officer, Director | Sold plan | 10,000 | $508.99 | $5.1M | Form 4 |
| Aug 31, 2026 | Joshua IsnerPresident | Sold plan | 16,775 | $574.43 | $9.6M | Form 4 |
| Aug 21, 2026 | Jeffrey C KuninsCpo & CTO | Sold plan | 9,605 | $626.70 | $6.0M | Form 4 |
| Aug 7, 2026 | Patrick W SmithChief Executive Officer, Director | Sold plan | 70 | $566.62 | $0.0M | Form 4 |
| Aug 7, 2026 | Patrick W SmithChief Executive Officer, Director | Sold plan | 9,930 | $548.77 | $5.4M | Form 4 |
| Jul 7, 2026 | Patrick W SmithChief Executive Officer, Director | Sold plan | 10,000 | $643.79 | $6.4M | Form 4 |
| Jun 29, 2026 | Patrick W SmithChief Executive Officer, Director | Sold plan | 10,000 | $500.00 | $5.0M | Form 4 |
| Jun 5, 2026 | Joshua IsnerPresident | Sold | 13,000 | $488.45 | $6.3M | Form 4 |
| Jun 4, 2026 | Patrick W SmithChief Executive Officer, Director | Sold plan | 20,000 | $500.00 | $10.0M | Form 4 |
| Jun 4, 2026 | Cameron BrooksChief Revenue Officer | Sold plan | 1,242 | $500.00 | $0.6M | Form 4 |
| Jun 4, 2026 | Elizabeth Reid CoughlinChief Human Officer | Sold | 1,554 | $485.00 | $0.8M | Form 4 |
| Jun 2, 2026 | Brittany BagleyCOO & CFO | Sold | 5,969 | $485.00 | $2.9M | Form 4 |
| Jun 1, 2026 | Caitlin Elizabeth KalinowskiDirector | Sold | 564 | $478.97 | $0.3M | Form 4 |
| Jun 1, 2026 | Jeri WilliamsDirector | Sold plan | 629 | $469.64 | $0.3M | Form 4 |
| May 22, 2026 | Isaiah FieldsChief Legal Officer | Sold | 2,000 | $400.00 | $0.8M | Form 4 |
| Mar 17, 2026 | Jeri WilliamsDirector | Sold plan | 157 | $490.00 | $0.1M | Form 4 |
| Mar 17, 2026 | Erika NardiniDirector | Sold | 198 | $506.58 | $0.1M | Form 4 |
| Mar 10, 2026 | Joshua IsnerPresident | Sold | 34,581 | $534.39 | $18.5M | Form 4 |
| Mar 9, 2026 | Cameron BrooksChief Revenue Officer | Sold plan | 1,221 | $565.51 | $0.7M | Form 4 |
| Mar 9, 2026 | Patrick W SmithChief Executive Officer, Director | Sold plan | 10,000 | $560.24 | $5.6M | Form 4 |
| Mar 2, 2026 | Jennifer H MakChief Accounting Officer | Sold | 1,500 | $573.45 | $0.9M | Form 4 |
| Mar 2, 2026 | Brittany BagleyCOO & CFO | Sold | 4,266 | $552.90 | $2.4M | Form 4 |
| Feb 27, 2026 | Isaiah FieldsChief Legal Officer | Sold | 2,000 | $535.01 | $1.1M | Form 4 |
| Feb 27, 2026 | Caitlin Elizabeth KalinowskiDirector | Sold | 930 | $535.35 | $0.5M | Form 4 |
| Feb 25, 2026 | Patrick W SmithChief Executive Officer, Director | Sold plan | 10,000 | $500.24 | $5.0M | Form 4 |
| Jan 7, 2026 | Patrick W SmithChief Executive Officer, Director | Sold plan | 10,000 | $619.01 | $6.2M | Form 4 |
| Dec 19, 2025 | Jennifer H MakChief Accounting Officer | Sold plan | 1,134 | $600.00 | $0.7M | Form 4 |
| Dec 11, 2025 | Brittany BagleyCOO & CFO | Sold | 2,000 | $580.00 | $1.2M | Form 4 |
| Dec 8, 2025 | Patrick W SmithChief Executive Officer, Director | Sold plan | 10,000 | $551.92 | $5.5M | Form 4 |
| Dec 8, 2025 | Joshua IsnerPresident | Sold | 20,000 | $552.60 | $11.1M | Form 4 |
| Dec 4, 2025 | Jeri WilliamsDirector | Sold | 100 | $550.63 | $0.1M | Form 4 |
| Dec 4, 2025 | Jennifer H MakChief Accounting Officer | Sold plan | 894 | $550.00 | $0.5M | Form 4 |
| Dec 3, 2025 | Joshua IsnerPresident | Sold plan | 2,041 | $535.11 | $1.1M | Form 4 |
| Dec 3, 2025 | Jennifer H MakChief Accounting Officer | Sold plan | 74 | $536.75 | $0.0M | Form 4 |
| Dec 2, 2025 | Jeffrey C KuninsCpo & CTO | Sold plan | 1,797 | $539.23 | $1.0M | Form 4 |
| Nov 10, 2025 | Brittany BagleyCOO & CFO | Sold | 2,500 | $610.00 | $1.5M | Form 4 |
| Nov 7, 2025 | Patrick W SmithChief Executive Officer, Director | Sold plan | 10,000 | $591.04 | $5.9M | Form 4 |
| Oct 7, 2025 | Patrick W SmithChief Executive Officer, Director | Sold plan | 10,000 | $713.74 | $7.1M | Form 4 |
Can it carry its debts, and how well does it use its money?
KIRA Β· Axon Enterprise owes $104M more than it holds in cash, about 4.9 years of operating profit.
Cash, debt and the ratios that show how comfortably Axon Enterprise can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $371M | $936M | $1.2B | $788M | $1.7B |
| Debt incl. finance leases | $0.0M | $674M | $677M | $680M | $1.8B |
| Net debt / EBITDA | β | β2.3x | β3.2x | β1.0x | 4.9x |
| Debt / equity | 0.0x | 0.5x | 0.4x | 0.3x | 0.6x |
| Interest coverage | β | β | 22.4x | 8.3x | β0.7x |
| Current ratio | 2.7x | 3.0x | 3.1x | 1.4x | 2.5x |
| Quick ratio | 2.4x | 2.7x | 2.8x | 1.2x | 2.3x |
| Total assets | $1.7B | $2.9B | $3.4B | $4.5B | $7.0B |
| Total liabilities | $640M | $1.6B | $1.8B | $2.1B | $3.8B |
| Shareholders' equity | $1.1B | $1.3B | $1.6B | $2.3B | $3.2B |
| Net debt (β = net cash) | β$371M | β$262M | β$565M | β$108M | $104M |
KIRA Β· Its return on capital was β2.2%: every 100 invested in the business earned about β2 in a year.
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Axon Enterprise passes 6 of 9 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | β | β | β |
| Cash from operations is positive | β | β | β |
| Return on assets rose | β | β | β |
| Cash from operations exceeds net income | β | β | β |
| Debt fell relative to assets | β | β | β |
| Current ratio rose | β | β | β |
| Share count didn't rise | β | β | β |
| Gross margin rose | β | β | β |
| Revenue rose relative to assets | β | β | β |
| F-score | 6 / 9 | 6 / 9 | 6 / 9 |
| Accruals ratio | β0.4% | β0.8% | β1.5% |
| Altman Z'' | 4.81 | 2.73 | 3.38 |
What does the share cost, and how does it compare?
KIRA Β· At $424.77 a share, the company is worth $35.0B: 176.3 times its earnings of the last four quarters.
Change the assumptions and see what they imply per share. These are models, not forecasts or price targets β the answer depends entirely on what you put in.
In plain words: Move the sliders to try your own guesses about growth. The result is what one share would be worth if those guesses came true. Different guesses give very different answers.
Value per share
β
Adds net cash of β$104M and divides by 82.4M diluted shares. Ten years of cash flows plus a terminal value, discounted to today.
Value per share
β
Reference multiples: today 174.4x Β· peers 32.0x Β· sector 26.0x.
KIRA Β· Axon Enterprise grew sales faster than 3 of its 4 similar companies. Its P/E is higher than 3 of 3.
Each companyβs latest fiscal year. Fiscal years end in different months, so periods donβt line up exactly.
In plain words: The same numbers for similar companies, so you can tell whether a figure is high or low for this kind of business.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score | |
|---|---|---|---|---|---|---|---|---|
| Axon Enterprise AXON | $35.0B | 33.5% | β2.2% | 2.7% | β2.2% | 176.3x | 6 | |
| BWX Technologies BWXT | $12.1B | 18.3% | 12.7% | 9.2% | 13.9% | 34.0x | 7 | Compare β |
| Curtiss-Wright CW | $17.7B | 12.1% | 18.1% | 15.8% | 15.9% | 32.8x | 8 | Compare β |
| Moog MOG-A | $11.5B | 7.0% | 11.7% | 3.3% | 11.7% | 30.5x | 7 | Compare β |
| AeroVironment AVAV | $6.2B | 140.9% | β15.7% | β7.1% | β9.1% | β | 3 | Compare β |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $268M | $344M | $420M | $531M | $681M | $863M | $1.2B | $1.6B | $2.1B | $2.8B |
| Gross profit | $171M | $207M | $259M | $307M | $416M | $541M | $726M | $956M | $1.2B | $1.7B |
| Research and development | $30.6M | $55.4M | $76.9M | $101M | $123M | $194M | $234M | $304M | $442M | $684M |
| Operating income | $31.9M | $13.0M | $24.8M | β$6.4M | β$14.1M | β$168M | $93.0M | $157M | $58.5M | β$62.1M |
| Interest expense | β | β | β | β | β | β | $0.0M | $7.0M | $7.1M | $94.2M |
| Pretax income | $31.5M | $15.8M | $28.1M | $2.1M | β$6.3M | β$141M | $196M | $157M | $382M | $19.0M |
| Income tax | $14.2M | $10.6M | β$1.1M | $1.2M | β$4.6M | β$81.4M | $49.3M | β$18.7M | $4.5M | β$106M |
| Net income | $17.3M | $5.2M | $29.2M | $0.9M | β$1.7M | β$60.0M | $147M | $176M | $377M | $125M |
| Diluted EPS | $0.32 | $0.10 | $0.50 | $0.01 | β$0.03 | β$0.91 | $2.03 | $2.33 | $4.80 | $1.51 |
| Diluted shares | 0.05B | 0.05B | 0.06B | 0.06B | 0.06B | 0.07B | 0.07B | 0.08B | 0.08B | 0.08B |
| Cash flow | ||||||||||
| Cash from operations | $21.1M | $18.5M | $63.9M | $65.7M | $38.5M | $125M | $235M | $189M | $408M | $211M |
| Capital expenditure | $5.0M | $10.4M | $11.1M | $15.9M | $72.6M | $49.9M | $55.8M | $59.6M | $78.8M | $136M |
| Free cash flow | $16.2M | $8.1M | $52.7M | $49.7M | β$34.2M | $74.6M | $180M | $130M | $330M | $75.1M |
| Depreciation and amortization | $3.7M | $8.0M | $10.6M | $11.4M | $12.5M | $18.7M | $23.1M | $19.3M | $48.4M | $83.2M |
| Stock-based compensation | $9.4M | $15.6M | $21.9M | $78.5M | $134M | $303M | $106M | $131M | $383M | $634M |
| Acquisitions | $3.5M | $10.6M | $5.0M | $0.0M | $0.0M | $22.4M | $2.1M | $21.1M | $622M | $647M |
| Share buybacks | $33.7M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Dividends paid | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Dividends and buybacks | $33.8M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $89.1M | $82.0M | $350M | $351M | $562M | $371M | $936M | $1.2B | $788M | $1.7B |
| Total debt | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $674M | $677M | $680M | $1.8B |
| Finance lease liabilities | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Current assets | $177M | $205M | $558M | $610M | $982M | $1.1B | $1.8B | $2.4B | $2.3B | $3.7B |
| Current liabilities | $78.0M | $108M | $166M | $196M | $256M | $419M | $603M | $762M | $1.7B | $1.5B |
| Inventory | $34.8M | $45.5M | $33.8M | $38.8M | $90.0M | $109M | $203M | $270M | $265M | $342M |
| Property and equipment, net | $24.0M | $31.2M | $37.9M | $43.8M | $106M | $139M | $170M | $201M | $247M | $331M |
| Total assets | $278M | $338M | $720M | $846M | $1.4B | $1.7B | $2.9B | $3.4B | $4.5B | $7.0B |
| Total liabilities | $127M | $171M | $252M | $302M | $405M | $640M | $1.6B | $1.8B | $2.1B | $3.8B |
| Shareholders' equity | $151M | $167M | $467M | $544M | $976M | $1.1B | $1.3B | $1.6B | $2.3B | $3.2B |
| Margins | ||||||||||
| Gross margin | 63.6% | 60.2% | 61.6% | 57.9% | 61.1% | 62.7% | 61.2% | 61.2% | 59.6% | 59.7% |
| Operating margin | 11.9% | 3.8% | 5.9% | β1.2% | β2.1% | β19.5% | 7.8% | 10.1% | 2.8% | β2.2% |
| EBITDA margin | 13.2% | 6.1% | 8.4% | 0.9% | β0.3% | β17.3% | 9.8% | 11.3% | 5.1% | 0.8% |
| Net margin | 6.5% | 1.5% | 7.0% | 0.2% | β0.3% | β7.0% | 12.4% | 11.3% | 18.1% | 4.5% |
| FCF margin | 6.0% | 2.3% | 12.6% | 9.4% | β5.0% | 8.6% | 15.1% | 8.3% | 15.8% | 2.7% |
| Returns | ||||||||||
| Return on capital | 32.1% | 8.8% | 24.4% | β2.1% | β3.7% | β24.3% | 8.3% | 15.2% | 3.5% | β2.2% |
| Return on capital employed | 16.3% | 6.1% | 6.3% | β1.1% | β1.6% | β14.0% | 5.3% | 6.4% | 2.2% | β1.5% |
| Return on equity | 11.2% | 3.3% | 9.2% | 0.2% | β0.2% | β5.9% | 12.7% | 12.2% | 19.1% | 4.5% |
| Return on assets | 6.8% | 1.7% | 5.5% | 0.1% | β0.2% | β3.9% | 6.5% | 5.6% | 9.6% | 2.2% |
| Growth | ||||||||||
| Revenue growth | 35.6% | 28.2% | 22.2% | 26.4% | 28.3% | 26.8% | 37.5% | 31.5% | 33.4% | 33.5% |
| Net income growth | β13.2% | β69.9% | 460.9% | β97.0% | β295.5% | β | β | 19.6% | 114.5% | β66.9% |
| EPS growth | β11.1% | β68.8% | 400.0% | β98.0% | β400.0% | β | β | 14.8% | 106.0% | β68.5% |
| FCF growth | β60.0% | β50.2% | 554.9% | β5.7% | β168.7% | β | 140.7% | β27.8% | 154.2% | β77.2% |
| Share count change | β2.0% | 0.7% | 7.5% | 3.6% | 2.9% | 7.1% | 9.6% | 4.0% | 4.1% | 4.9% |
| Financial health | ||||||||||
| Net debt / EBITDA | β2.5x | β3.9x | β9.9x | β70.6x | β | β | β2.3x | β3.2x | β1.0x | 4.9x |
| Debt / equity | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x | 0.5x | 0.4x | 0.3x | 0.6x |
| Interest coverage | β | β | β | β | β | β | β | 22.4x | 8.3x | β0.7x |
| Current ratio | 2.3x | 1.9x | 3.4x | 3.1x | 3.8x | 2.7x | 3.0x | 3.1x | 1.4x | 2.5x |
| Quick ratio | 1.8x | 1.5x | 3.2x | 2.9x | 3.5x | 2.4x | 2.7x | 2.8x | 1.2x | 2.3x |
| Capital allocation | ||||||||||
| Capex / revenue | 1.9% | 3.0% | 2.7% | 3.0% | 10.7% | 5.8% | 4.7% | 3.8% | 3.8% | 4.9% |
| Stock comp / revenue | 3.5% | 4.5% | 5.2% | 14.8% | 19.6% | 35.1% | 8.9% | 8.4% | 18.4% | 22.8% |
| Payouts / FCF | 208.6% | 0.0% | 0.0% | 0.0% | β | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Quality scores | ||||||||||
| Piotroski F-score | 6.0 | 4.0 | 7.0 | 3.0 | 5.0 | 3.0 | 6.0 | 6.0 | 6.0 | 6.0 |
| Altman Z'' | 5.7 | 4.4 | 6.5 | 5.7 | 6.3 | 4.0 | 4.1 | 4.8 | 2.7 | 3.4 |
| Accruals ratio | β1.5% | β4.3% | β6.6% | β8.3% | β3.6% | β12.0% | β3.9% | β0.4% | β0.8% | β1.5% |
Source: SEC EDGAR XBRL filings (CIK 0001069183). Data updated October 9, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
